Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129039) titled 'A retrospective controlled study of chemotherapy combined with bevacizumab versus chemotherapy combined with ivonescimab in the treatment of EGFR-TKI-resistant advanced NSCLC' on July 29.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Peking University Shenzhen Hospital
Condition:
EGFR-mutant non-small cell lung cancer
Intervention:
Control group:none
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2024-10-01
Target Sample Size: Control group:26;Experimental group:14;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/sh...